The non-receptor tyrosine kinase Src is important for many aspects of cell physiology. The viral src gene was the first retroviral oncogene to be identified, and its cellular counterpart was the ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 31.43%, which has investors questioning if this is right time ...

KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel Pharmaceuticals KFDA greenlights Tavalisse, a groundbreaking therapy for rare platelet disorder by Rigel Pharmaceuticals.

Approximately 213,380 new cases of non-small-cell ... between two receptors within the cell membrane, and an intracellular domain that contains the tyrosine kinase enzymatic activity.

Advanced non-small-cell lung cancer ... pathways downstream of activated erbB receptor tyrosine kinases. The Ras–MAPK (mitogen-activated protein kinase) pathway is another important cell ...

There's at least 25 drugs in the development by companies and different university in the domain of vasculitis. The key target in these medication include tyrosine, protein kinase, JAK one, JAK two, ...

The c-Met protein is a receptor tyrosine kinase that mediates cell proliferation, survival, and angiogenesis, and can be ...